December 6, 2024:

A Big Ten Cancer Research Consortium (Big Ten CRC) trial titled, “A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042” has been accepted as a poster presentation (P2-07-21) at the 2024 San Antonio Breast Cancer Symposium on December 11, 2024 from 5:30 pm – 7:30 pm.

Congratulations to all co-authors and study teams involved in the study!

(From left to right: Chan, Omene, Baka, Wang)

Led by sponsor-investigator Nancy Chan, MD (now at New York University), and co-investigator Coral Omene, MD, PhD, of Rutgers Cancer Institute of New Jersey, this study explores the anti-tumor activity of pembrolizumab with fulvestrant as measured by RECIST 1.1 tumor response and by progression free survival. NYU contributors to this work included Nadia Baka, MD, and Jacqueline Wang, MD.

This is a non-randomized, multi-site, open-label Phase II trial for subjects with metastatic, hormone receptor positive, HER2 negative breast cancer. Researchers expected that if the immune response were augmented by the addition of pembrolizumab, significant change in durability of response would be noted. Patients were treated with pembrolizumab dosed at 200 mg intravenous infusion in combination with standard fulvestrant 500mg intramuscular injection.

Learn more about this study: https://www.clinicaltrials.gov/study/NCT03393845

View SABCS session information.

About the Big Ten Cancer Research Consortium: The Big Ten Cancer Research Consortium was created in 2013 to transform the conduct of cancer research through collaborative clinical trials and observational studies that seek to improve the lives of cancer patients in the diverse communities we serve by leveraging the scientific and clinical expertise of Big Ten universities. The Big Ten Cancer Research Consortium creates a unique team research culture to drive science rapidly from ideas to treatment and prevention. Within this innovative environment, today’s research leaders collaborate with and mentor the research leaders of tomorrow. Since its founding, the Big Ten CRC has activated nearly 40 clinical trials across a wide range of cancer types, more than 1,000 participants have enrolled in Big Ten CRC studies, and more than 500 researchers have joined Big Ten CRC Clinical Trial Working Groups.

About the Big Ten Conference: The Big Ten Conference is an association of world-class universities whose member institutions share a common mission of research, graduate, professional and undergraduate teaching and public service. Founded in 1896, the Big Ten has sustained a comprehensive set of shared practices and policies that enforce the priority of academics in the lives of students competing in intercollegiate athletics and emphasize the values of integrity, fairness and competitiveness. The broad-based programs of the 18 Big Ten institutions provide direct financial support for more than 11,000 participation opportunities on 350 teams in 42 different sports. The Big Ten sponsors 28 official conference sports, 14 for men and 14 for women. For more information, visit www.bigten.org.